Inh Agepha (Isoniazid)

Isoniazid blocks the enzyme InhA, which is essential for the synthesis of mycolic acids—key components of the Mycobacterium tuberculosis cell wall. By preventing mycolic acid formation, the drug weakens the bacterial cell envelope, leading to cell death, especially in rapidly dividing bacilli.

The prescribed dose is determined by the treating clinician based on factors such as patient weight, disease form (active or latent), and renal function. Typical adult regimens range from 5 mg/kg up to 300 mg once daily, but exact dosing must follow local clinical guidelines and the prescriber's judgment.

Safety data for isoniazid during pregnancy and lactation are limited, and the product does not have a definitive pregnancy category. It may be used when the expected benefit outweighs potential risks, and pyridoxine supplementation is recommended to reduce the chance of neuropathy. Breastfeeding mothers should consult their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Rifampicin is the most common companion drug in TB regimens. While rifampicin has a broader spectrum and induces hepatic enzymes, isoniazid is highly bactericidal against actively replicating mycobacteria but carries a higher risk of hepatotoxicity and peripheral neuropathy. Both are essential components of standard therapy, and their combined use enhances efficacy.

Inh Agepha should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments to maintain stability.

Inh Agepha is taken orally, usually once daily. The tablet should be swallowed whole with a full glass of water; it may be taken with or without food, although taking it with food can reduce gastrointestinal upset. Patients should follow the dosing schedule prescribed by their healthcare professional.

The most serious adverse events include hepatotoxicity, which can manifest as elevated liver enzymes, hepatitis or, rarely, liver failure; severe peripheral neuropathy, especially in patients with pre‑existing nerve disorders; and rare hypersensitivity reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Prompt medical evaluation is required if these symptoms appear.

Inh Agepha is contraindicated in individuals with known hypersensitivity to isoniazid or any of its excipients. Patients with severe pre‑existing liver disease, acute hepatic failure, or those who have experienced severe drug‑induced liver injury should avoid its use. Caution is also advised for patients with significant peripheral neuropathy.